Cargando…

An inactivating human TRPC6 channel mutation without focal segmental glomerulosclerosis

Transient receptor potential cation channel-6 (TRPC6) gene mutations cause familial focal segmental glomerulosclerosis (FSGS), which is inherited as an autosomal dominant disease. In patients with TRPC6-related FSGS, all mutations map to the N- or C-terminal TRPC6 protein domains. Thus far, the majo...

Descripción completa

Detalles Bibliográficos
Autores principales: Batool, Lilas, Hariharan, Krithika, Xu, Yao, Kaßmann, Mario, Tsvetkov, Dmitry, Gohlke, Björn-Oliver, Kaden, Sylvia, Gossen, Manfred, Nürnberg, Bernd, Kurtz, Andreas, Gollasch, Maik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449997/
https://www.ncbi.nlm.nih.gov/pubmed/37615749
http://dx.doi.org/10.1007/s00018-023-04901-w
_version_ 1785095093209792512
author Batool, Lilas
Hariharan, Krithika
Xu, Yao
Kaßmann, Mario
Tsvetkov, Dmitry
Gohlke, Björn-Oliver
Kaden, Sylvia
Gossen, Manfred
Nürnberg, Bernd
Kurtz, Andreas
Gollasch, Maik
author_facet Batool, Lilas
Hariharan, Krithika
Xu, Yao
Kaßmann, Mario
Tsvetkov, Dmitry
Gohlke, Björn-Oliver
Kaden, Sylvia
Gossen, Manfred
Nürnberg, Bernd
Kurtz, Andreas
Gollasch, Maik
author_sort Batool, Lilas
collection PubMed
description Transient receptor potential cation channel-6 (TRPC6) gene mutations cause familial focal segmental glomerulosclerosis (FSGS), which is inherited as an autosomal dominant disease. In patients with TRPC6-related FSGS, all mutations map to the N- or C-terminal TRPC6 protein domains. Thus far, the majority of TRPC6 mutations are missense resulting in increased or decreased calcium influx; however, the fundamental molecular mechanisms causing cell injury and kidney pathology are unclear. We report a novel heterozygous TRPC6 mutation (V691Kfs*) in a large kindred with no signs of FSGS despite a largely truncated TRPC6 protein. We studied the molecular effects of V691Kfs* TRPC6 mutant using the tridimensional cryo-EM structure of the tetrameric TRPC6 protein. The results indicated that V691 is localized at the pore-forming transmembrane region affecting the ion conduction pathway, and predicted that V691Kfs* causes closure of the ion-conducting pathway leading to channel inactivation. We assessed the impact of V691Kfs* and two previously reported TRPC6 disease mutants (P112Q and G757D) on calcium influx in cells. Our data show that the V691Kfs* fully inactivated the TRCP6 channel-specific calcium influx consistent with a complete loss-of-function phenotype. Furthermore, the V691Kfs* truncation exerted a dominant negative effect on the full-length TRPC6 proteins. In conclusion, the V691Kfs* non-functional truncated TRPC6 is not sufficient to cause FSGS. Our data corroborate recently characterized TRPC6 loss-of-function and gain-of-function mutants suggesting that one defective TRPC6 gene copy is not sufficient to cause FSGS. We underscore the importance of increased rather than reduced calcium influx through TRPC6 for podocyte cell death. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00018-023-04901-w.
format Online
Article
Text
id pubmed-10449997
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-104499972023-08-26 An inactivating human TRPC6 channel mutation without focal segmental glomerulosclerosis Batool, Lilas Hariharan, Krithika Xu, Yao Kaßmann, Mario Tsvetkov, Dmitry Gohlke, Björn-Oliver Kaden, Sylvia Gossen, Manfred Nürnberg, Bernd Kurtz, Andreas Gollasch, Maik Cell Mol Life Sci Original Article Transient receptor potential cation channel-6 (TRPC6) gene mutations cause familial focal segmental glomerulosclerosis (FSGS), which is inherited as an autosomal dominant disease. In patients with TRPC6-related FSGS, all mutations map to the N- or C-terminal TRPC6 protein domains. Thus far, the majority of TRPC6 mutations are missense resulting in increased or decreased calcium influx; however, the fundamental molecular mechanisms causing cell injury and kidney pathology are unclear. We report a novel heterozygous TRPC6 mutation (V691Kfs*) in a large kindred with no signs of FSGS despite a largely truncated TRPC6 protein. We studied the molecular effects of V691Kfs* TRPC6 mutant using the tridimensional cryo-EM structure of the tetrameric TRPC6 protein. The results indicated that V691 is localized at the pore-forming transmembrane region affecting the ion conduction pathway, and predicted that V691Kfs* causes closure of the ion-conducting pathway leading to channel inactivation. We assessed the impact of V691Kfs* and two previously reported TRPC6 disease mutants (P112Q and G757D) on calcium influx in cells. Our data show that the V691Kfs* fully inactivated the TRCP6 channel-specific calcium influx consistent with a complete loss-of-function phenotype. Furthermore, the V691Kfs* truncation exerted a dominant negative effect on the full-length TRPC6 proteins. In conclusion, the V691Kfs* non-functional truncated TRPC6 is not sufficient to cause FSGS. Our data corroborate recently characterized TRPC6 loss-of-function and gain-of-function mutants suggesting that one defective TRPC6 gene copy is not sufficient to cause FSGS. We underscore the importance of increased rather than reduced calcium influx through TRPC6 for podocyte cell death. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00018-023-04901-w. Springer International Publishing 2023-08-24 2023 /pmc/articles/PMC10449997/ /pubmed/37615749 http://dx.doi.org/10.1007/s00018-023-04901-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Batool, Lilas
Hariharan, Krithika
Xu, Yao
Kaßmann, Mario
Tsvetkov, Dmitry
Gohlke, Björn-Oliver
Kaden, Sylvia
Gossen, Manfred
Nürnberg, Bernd
Kurtz, Andreas
Gollasch, Maik
An inactivating human TRPC6 channel mutation without focal segmental glomerulosclerosis
title An inactivating human TRPC6 channel mutation without focal segmental glomerulosclerosis
title_full An inactivating human TRPC6 channel mutation without focal segmental glomerulosclerosis
title_fullStr An inactivating human TRPC6 channel mutation without focal segmental glomerulosclerosis
title_full_unstemmed An inactivating human TRPC6 channel mutation without focal segmental glomerulosclerosis
title_short An inactivating human TRPC6 channel mutation without focal segmental glomerulosclerosis
title_sort inactivating human trpc6 channel mutation without focal segmental glomerulosclerosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449997/
https://www.ncbi.nlm.nih.gov/pubmed/37615749
http://dx.doi.org/10.1007/s00018-023-04901-w
work_keys_str_mv AT batoollilas aninactivatinghumantrpc6channelmutationwithoutfocalsegmentalglomerulosclerosis
AT hariharankrithika aninactivatinghumantrpc6channelmutationwithoutfocalsegmentalglomerulosclerosis
AT xuyao aninactivatinghumantrpc6channelmutationwithoutfocalsegmentalglomerulosclerosis
AT kaßmannmario aninactivatinghumantrpc6channelmutationwithoutfocalsegmentalglomerulosclerosis
AT tsvetkovdmitry aninactivatinghumantrpc6channelmutationwithoutfocalsegmentalglomerulosclerosis
AT gohlkebjornoliver aninactivatinghumantrpc6channelmutationwithoutfocalsegmentalglomerulosclerosis
AT kadensylvia aninactivatinghumantrpc6channelmutationwithoutfocalsegmentalglomerulosclerosis
AT gossenmanfred aninactivatinghumantrpc6channelmutationwithoutfocalsegmentalglomerulosclerosis
AT nurnbergbernd aninactivatinghumantrpc6channelmutationwithoutfocalsegmentalglomerulosclerosis
AT kurtzandreas aninactivatinghumantrpc6channelmutationwithoutfocalsegmentalglomerulosclerosis
AT gollaschmaik aninactivatinghumantrpc6channelmutationwithoutfocalsegmentalglomerulosclerosis
AT batoollilas inactivatinghumantrpc6channelmutationwithoutfocalsegmentalglomerulosclerosis
AT hariharankrithika inactivatinghumantrpc6channelmutationwithoutfocalsegmentalglomerulosclerosis
AT xuyao inactivatinghumantrpc6channelmutationwithoutfocalsegmentalglomerulosclerosis
AT kaßmannmario inactivatinghumantrpc6channelmutationwithoutfocalsegmentalglomerulosclerosis
AT tsvetkovdmitry inactivatinghumantrpc6channelmutationwithoutfocalsegmentalglomerulosclerosis
AT gohlkebjornoliver inactivatinghumantrpc6channelmutationwithoutfocalsegmentalglomerulosclerosis
AT kadensylvia inactivatinghumantrpc6channelmutationwithoutfocalsegmentalglomerulosclerosis
AT gossenmanfred inactivatinghumantrpc6channelmutationwithoutfocalsegmentalglomerulosclerosis
AT nurnbergbernd inactivatinghumantrpc6channelmutationwithoutfocalsegmentalglomerulosclerosis
AT kurtzandreas inactivatinghumantrpc6channelmutationwithoutfocalsegmentalglomerulosclerosis
AT gollaschmaik inactivatinghumantrpc6channelmutationwithoutfocalsegmentalglomerulosclerosis